Roche raises Genentech bid to $45.7bn

Roche has upped its offer for Genentech to $93 a share, believing that this will be sufficient to bring the drawn out takeover to a close.

The bid is still a long way short of the $112 that Genentech is alleged to have valued itself at, according to a Roche filing with the US Securities and Exchange Commission.

Despite this, and the possibility that positive data from Avastin trials could send Genentech’s share price over $100, Franz Humer, chairman of the Roche Group, is confident the deal will go through.

Genentech has urged shareholders not to act until the Special Committee has taken a formal position, which will happen “promptly”.




Be part of XTractor community.

  • XTractor the first of its kind - Literature alert service, provides manually curated & annotated sentences for the Keywords of your choice
  • XTractor maps, extracted entities (genes, processes, drugs, diseases etc) to multiple ontologies
  • Enables customized report generation. With XTractor the sentences are categorized into biologically significant relationships
  • The categorized sentences could then be tagged and shared across multiple users
  • Provides users with the ability to create his own database for a set of Key terms
  • Users could change the Keywords of preference from time to time, with changing research needs
  • XTractor thus proves to be a platform for getting real-time highly accurate data along with the ability to Share and collaborate


Sign up it's free, and takes less than a minute. Just click here:www.xtractor.in.











Comments

Popular posts from this blog

Sequence Analysis is still sexy:Dual Descriptor Method for Biological Sequence Analysis

Abbott Laboratories Buys Piramal Healthcare Limited Biz for $3.72B

List of Cheminformatics Companies & Institutions